Wang et al., 2024 - Google Patents
The value of adjusted PSAD in prostate cancer detection in the Chinese populationWang et al., 2024
View HTML- Document ID
- 4948459768811235808
- Author
- Wang F
- Fu M
- Tang Y
- Li J
- Publication year
- Publication venue
- Frontiers in Oncology
External Links
Snippet
Objective To investigate the value of adjusted prostate-specific antigen density (PSADadj) in the diagnosis of prostate cancer (PCa). Methods Data from 410 patients who underwent transrectal ultrasound-guided prostate biopsy were retrospectively analyzed in Beijing …
- 206010060862 Prostate cancer 0 title abstract description 22
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/34—Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
- G06F19/345—Medical expert systems, neural networks or other automated diagnosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lawrentschuk et al. | ‘Prostatic evasive anterior tumours’: the role of magnetic resonance imaging | |
| Puech et al. | Dynamic contrast-enhanced–magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens | |
| Porpiglia et al. | The roles of multiparametric magnetic resonance imaging, PCA3 and Prostate Health Index—which is the best predictor of prostate cancer after a negative biopsy? | |
| Porpiglia et al. | In‐parallel comparative evaluation between multiparametric magnetic resonance imaging, prostate cancer antigen 3 and the prostate health index in predicting pathologically confirmed significant prostate cancer in men eligible for active surveillance | |
| Ross et al. | Clarifying the PSA grey zone: The management of patients with a borderline PSA | |
| Giganti et al. | Apparent diffusion coefficient in the evaluation of side-specific extracapsular extension in prostate cancer: development and external validation of a nomogram of clinical use | |
| Lu et al. | Negative multiparametric magnetic resonance imaging of the prostate predicts absence of clinically significant prostate cancer on 12-core template prostate biopsy | |
| Lantz et al. | Expanding active surveillance inclusion criteria: a novel nomogram including preoperative clinical parameters and magnetic resonance imaging findings | |
| Wei et al. | Biparametric prostate MRI and clinical indicators predict clinically significant prostate cancer in men with “gray zone” PSA levels | |
| Wang et al. | PI-RADS version 2.1 scoring system is superior in detecting transition zone prostate cancer: a diagnostic study | |
| Lim et al. | When to biopsy Prostate Imaging and Data Reporting System version 2 (PI-RADSv2) assessment category 3 lesions? Use of clinical and imaging variables to predict cancer diagnosis at targeted biopsy | |
| Zou et al. | Value of serum free prostate-specific antigen density in the diagnosis of prostate cancer | |
| Wei et al. | Prediction of postprostatectomy biochemical recurrence using quantitative ultrasound shear wave elastography imaging | |
| Chen et al. | The prediction value of PI-RADS v2 score in high-grade Prostate Cancer: a multicenter retrospective study | |
| Chen et al. | Simple vascular architecture classification in predicting pancreatic neuroendocrine tumor grade and prognosis | |
| Zhou et al. | Development of a nomogram combining multiparametric magnetic resonance imaging and PSA‐related parameters to enhance the detection of clinically significant cancer across different region | |
| Wen et al. | PI-RADS v2. 1 combined with prostate-specific antigen density for detection of prostate cancer in peripheral zone | |
| Ma et al. | Developing a predictive model for clinically significant prostate cancer by combining age, PSA density, and mpMRI | |
| Wang et al. | The value of adjusted PSAD in prostate cancer detection in the Chinese population | |
| MacAskill et al. | Diagnostic value of MRI-based PSA density in predicting transperineal sector-guided prostate biopsy outcomes | |
| Jiang et al. | MRI-based nomogram of prostate maximum sectional area and its zone area for prediction of prostate cancer | |
| Zhao et al. | Interpretable machine learning model for predicting clinically significant prostate cancer: integrating intratumoral and peritumoral radiomics with clinical and metabolic features | |
| Zhang et al. | Development of a prediction model for the risk of recurrent laryngeal nerve lymph node metastasis in thoracolaparoscopic esophagectomy with cervical anastomosis | |
| Nuo et al. | Efficacy of 68Ga-PSMA-11 PET/CT with biparametric MRI in diagnosing prostate cancer and predicting risk stratification: a comparative study | |
| Masters et al. | Free/total serum prostate‐specific antigen ratio: how helpful is it in detecting prostate cancer? |